166 related articles for article (PubMed ID: 3934801)
1. Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri(n-butyl)phosphate detergent combinations.
Horowitz B; Wiebe ME; Lippin A; Stryker MH
Transfusion; 1985; 25(6):516-22. PubMed ID: 3934801
[TBL] [Abstract][Full Text] [Related]
2. The use of tri(n-butyl)phosphate detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasma's subsequent fractionation.
Piët MP; Chin S; Prince AM; Brotman B; Cundell AM; Horowitz B
Transfusion; 1990 Sep; 30(7):591-8. PubMed ID: 2402772
[TBL] [Abstract][Full Text] [Related]
3. Sterilisation of hepatitis and HTLV-III viruses by exposure to tri(n-butyl)phosphate and sodium cholate.
Prince AM; Horowitz B; Brotman B
Lancet; 1986 Mar; 1(8483):706-10. PubMed ID: 2870224
[TBL] [Abstract][Full Text] [Related]
4. Tri(n-butyl) phosphate/detergent treatment of licensed therapeutic and experimental blood derivatives.
Edwards CA; Piet MP; Chin S; Horowitz B
Vox Sang; 1987; 52(1-2):53-9. PubMed ID: 3111089
[TBL] [Abstract][Full Text] [Related]
5. Resistance of vaccinia virus to inactivation by solvent/detergent treatment of blood products.
Roberts P
Biologicals; 2000 Mar; 28(1):29-32. PubMed ID: 10799053
[TBL] [Abstract][Full Text] [Related]
6. Comparable virus inactivation by bovine or vegetable derived Tween 80 during solvent/detergent treatment.
Seitz H; Blümel J; Schmidt I; Willkommen H; Löwer J
Biologicals; 2002 Sep; 30(3):197-205. PubMed ID: 12217344
[TBL] [Abstract][Full Text] [Related]
7. Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma.
Horowitz B; Bonomo R; Prince AM; Chin SN; Brotman B; Shulman RW
Blood; 1992 Feb; 79(3):826-31. PubMed ID: 1310064
[TBL] [Abstract][Full Text] [Related]
8. Inactivation of viruses in labile blood derivatives. II. Physical methods.
Horowitz B; Wiebe ME; Lippin A; Vandersande J; Stryker MH
Transfusion; 1985; 25(6):523-7. PubMed ID: 3934802
[TBL] [Abstract][Full Text] [Related]
9. Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies.
Dichtelmüller HO; Biesert L; Fabbrizzi F; Gajardo R; Gröner A; von Hoegen I; Jorquera JI; Kempf C; Kreil TR; Pifat D; Osheroff W; Poelsler G
Transfusion; 2009 Sep; 49(9):1931-43. PubMed ID: 19497061
[TBL] [Abstract][Full Text] [Related]
10. Investigations into the application of tri(n-butyl)phosphate/detergent mixtures to blood derivatives.
Horowitz B
Curr Stud Hematol Blood Transfus; 1989; (56):83-96. PubMed ID: 2642786
[No Abstract] [Full Text] [Related]
11. Quantitative determination of residual sodium-cholate in tri(N-butyl)phosphate/sodium-cholate treated factor VIII-preparations.
Dengler T; Kellner S; Fürst G
Vox Sang; 1989; 57(3):161-3. PubMed ID: 2515653
[TBL] [Abstract][Full Text] [Related]
12. Virus inactivation in a factor VIII/VWF concentrate treated using a solvent/detergent procedure based on polysorbate 20.
Roberts PL; Lloyd D; Marshall PJ
Biologicals; 2009 Jan; 37(1):26-31. PubMed ID: 18848782
[TBL] [Abstract][Full Text] [Related]
13. Viral safety of solvent-detergent treated blood products.
Horowitz B; Prince AM; Horowitz MS; Watklevicz C
Dev Biol Stand; 1993; 81():147-61. PubMed ID: 8174797
[TBL] [Abstract][Full Text] [Related]
14. Sindbis virus as a tool for quality control of viral inactivation of heated and chemically treated plasma-derived products.
Espíndola OM; Belluci MS; Oliveira BC; Liberto MI; Cabral MC
J Virol Methods; 2006 Jun; 134(1-2):171-5. PubMed ID: 16507321
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of hepatitis B and Hutchinson strain non-A, non-B hepatitis viruses by exposure to Tween 80 and ether.
Prince AM; Horowitz B; Brotman B; Huima T; Richardson L; van den Ende MC
Vox Sang; 1984; 46(1):36-43. PubMed ID: 6422634
[TBL] [Abstract][Full Text] [Related]
16. [Development and characterization of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
Ristol P; Gensana M; Fernández J; Massot M; Bhattacharya P; Jorquera JI
Sangre (Barc); 1996 Apr; 41(2):125-30. PubMed ID: 9045352
[TBL] [Abstract][Full Text] [Related]
17. Large-scale gel filtration chromatography for the production of a solvent/detergent-treated high-purity factor VIII concentrate.
Dengler T; Stöcker U; Kellner S; Fürst G
Vox Sang; 1990; 58(4):257-63. PubMed ID: 1697997
[TBL] [Abstract][Full Text] [Related]
18. A minipool process for solvent-detergent treatment of cryoprecipitate at blood centres using a disposable bag system.
Burnouf T; Goubran HA; Radosevich M; Sayed MA; Gorgy G; El-Ekiaby M
Vox Sang; 2006 Jul; 91(1):56-62. PubMed ID: 16756602
[TBL] [Abstract][Full Text] [Related]
19. Disruption of influenza virus A by diethylether-Tween and tri-N-butyl phosphate-Tween mixtures.
Danihelková H; Závadová H
Acta Virol; 1984 Jan; 28(1):26-32. PubMed ID: 6143494
[TBL] [Abstract][Full Text] [Related]
20. Purification of fibroblast growth factor-2 from human placenta using tri(n-butyl)phosphate and sodium cholate.
Wolff P; Tanaka AM; Chenker E; Cabrera-Crespo J; Raw I; Ho PL
Biochimie; 1996; 78(3):190-4. PubMed ID: 8831950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
